EyePoint Pharmaceuticals Inc
EYPT
Company Profile
Business description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Contact
480 Pleasant Street
Suite A-210
WatertownMA02472
USAT: +1 617 926-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
144
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,341.00 | 53.10 | 0.64% |
| CAC 40 | 7,584.88 | 29.01 | 0.38% |
| DAX 40 | 22,539.42 | 113.59 | 0.51% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,467.31 | 3.85 | 0.05% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 36,045.38 | 205.39 | 0.57% |
| NZX 50 Index | 11,903.31 | 122.14 | -1.02% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,126.20 | 55.60 | 0.69% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |